전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
refraktaarne kll:
refractory cll:
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
retsidiveerunud/ refraktaarne ph+ all.
relapsed/ refractory ph+ all:
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
retsidiveerunud/refraktaarne follikulaarne lümfoom
relapsed/refractory follicular lymphoma
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
lisateave vt lõik 5.1. refraktaarne kll:
see section 5.1 for further information.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
hüponatreemia, hüperkaltseemia, sümptomaatiline hüperurikeemia ja refraktaarne hüpokaleemia.
hyponatraemia, hypercalcaemia, symptomatic hyperuricaemia and refractory hypokalaemia.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
monoteraapiana täiskasvanud patsientidel, kellel on retsidiveerunud või refraktaarne ph+ all.
adult patients with relapsed or refractory ph+ all as monotherapy.
마지막 업데이트: 2012-04-11
사용 빈도: 1
품질:
samamoodi tuleb hinnata riski ja kasu vahekorda rapamunega ravi jätkamisel patsientidel, kellel on raskekujuline refraktaarne hüperlipideemia.
similarly the risk/benefit of continued rapamune therapy should be re-evaluated in patients with severe refractory hyperlipidaemia.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
samamoodi tuleb hinnata riski ja kasu vahekorda rapamune’ ga ravi jätkamisel patsientidel, kellel on raskekujuline refraktaarne hüperlipideemia.
similarly the risk/ benefit of continued rapamune therapy should be re-evaluated in patients with severe refractory hyperlipidemia.
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
blincyto kliinilistes uuringutes osales kokku 225 patsienti vanuses ≥ 18 aastat, kellel oli retsidiveerunud või refraktaarne b-eellasrakuline all.
a total of 225 patients aged ≥ 18 years of age with relapsed or refractory b-precursor all were exposed to blincyto during clinical trials.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
blincyto toimet lastele, kellel oli retsidiveerunud ja refraktaarne b- eellasrakuline all, on hinnatud i/ii faasi annuse suurendamise ja hindamise uuringus.
blincyto has been evaluated in paediatric patients with relapsed or refractory b-precursor all in a phase i/ii dose escalation/evaluation study.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
blincyto on näidustatud täiskasvanute raviks, kellel on philadelphia kromosoom-negatiivne retsidiveerunud või refraktaarne b-eellasrakuline äge lümfoblastleukeemia (all).
blincyto is indicated for the treatment of adults with philadelphia chromosome negative relapsed or refractory b-precursor acute lymphoblastic leukaemia (all).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
eriti näitasid post-hoc analüüsi andmed 2172 patsiendi kohta (17 % cure kogupopulatsioonist), kellele paigaldati võrktoru (koronaarstent) (stent-cure), et võrreldes platseeboga näitas klopidogreel märkimisväärset suhtelise riski vähenemist (rrr) 26,2 % esmase kombineeritud tulemusnäitaja osas (surm kardiovaskulaarsel põhjusel, mi, insult) ning 23,9 % teise esmase kombineeritud tulemusnäitaja osas (surm kardiovaskulaarsel põhjusel, mi, insult või refraktaarne isheemia).
in particular, in a post-hoc analysis in 2,172 patients (17% of the total cure population) who underwent stent placement (stent-cure), the data showed that clopidogrel compared to placebo, demonstrated a significant rrr of 26.2% favouring clopidogrel for the co-primary endpoint (cv death, mi, stroke) and also a significant rrr of 23.9% for the second co-primary endpoint (cv death, mi, stroke or refractory ischaemia).
마지막 업데이트: 2017-04-26
사용 빈도: 7
품질: